8-6-04

| 1334 |
|------|
| |

PTO/SB/21 (6-99)

Please type a grus sign (+) inside this box []

Approved for se through 09/30/2000. OMB 0651-0031 Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Reperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. SCAN WEST 10/714,195 Application Number November 14, 2003 **TRANSMITTAL** Filing Date **FORM** First Named Inventor Joffre B. Baker, et al. (to be used for all correspondence after initial filing) 1634 Group/Art Unit Examiner Name Unassigned Total Number of Pages in This Submission 77 pgs. 39740-0005A Attorney Docket Number ENCLOSURES (check all that apply) After Allowance Communication **Assignment Papers** Fee Transmittal Form (for an Application) to Group Appeal Communication to Board Drawing(s) Fee Attached of Appeals and Interferences Appeal Communication to Group Amendment / Response Licensing-related Papers (Appeal Notice, Brief, Reply Brief) After Final Petition Routing Slip (PTO/SB/69) Proprietary Information and Accompanying Petition Version with Markings Showing Petition to Convert to a Status Letter Changes **Provisional Application** Affidavits/declaration(s) Power of Attorney, Revocation Additional Enclosure(s) Change of Correspondence Address (please identify below): **Extension of Time Request** stamped return postcard; Terminal Disclaimer PTO Form 1449; Information Disclosure Statement copies of 10 cited reference Small Entity Statement Certified Copy of Priority Request for Refund Document(s) Response to Missing Parts/ Remarks Incomplete Application **AUTHORIZATION TO CHARGE DEPOSIT ACCOUNT 08-1641 FOR ANY FEES** Response to Missing DUE IN CONNECTION WITH THIS PAPER. Parts under 37 CFR 1.52 or 1.53 SIGNATURE OF APPLICANT, ATTORNEY OR AGENT Firm Ginger R. Dreger, Reg. No. 33,055 HELLER EHRMAN WHITE & McAULIFFE LLP Individual name Signature Date Customer Number: 25213 August 4, 2004 **CERTIFICATE OF MAILING** I hereby certify that this correspondence is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. §1.10 on the date indicated below and addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on this date: August 4, 2004. Typed or printed name Sandra Puljic August 4, 2004 Date Signature

CERTIFICATE OF EXPRESS MAILING Thereby certify that this correspondence is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. §1.10 on the date indicated below and addressed to: Mail Stop: Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on this date: August 4, 2004 Express Mail Label EL 993 692 178 US Typed or printed name Sandra Puljic Date Signature

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Baker, et al.

Docket No.:

39740-0005A

Serial No.:

10/714,195

Group Art Unit:

1634

Filing Date:

11/14/2003

Examiner:

Unassigned

For:

GENE EXPRESSION PROFILING OF EGFR POSITIVE CANCER

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §1.97

Mail Stop: Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Listed below or on an attached Form PTO-1449 is information known to applicant(s). A copy of each listed publication and U.S. and foreign patent, except for pending U.S. applications, is being submitted herewith, along with a concise explanation of information in a foreign language, if any, pursuant to 37 C.F.R. §1.97-1.98. In accordance with the USPTO waiver of 37 CFR 1.98 (a)(2)(i), which appears in the USPTO Official Gazette Notices dated August 5, 2003, the applicant is not providing copies of the listed U.S. patents and patent publications.

Applicants respectfully request that the listed information be considered by the Examiner and be made of record in the above-identified application. If form PTO-1449 is enclosed, the Examiner is requested to initial and return it in accordance with MPEP §609.

This statement is not intended to represent that a search has been made or that the information cited in the statement is, or is considered to be, material to patentability as defined in §1.56.

08/09/2004 EABUBAK1 00000056 081641 10714195 180.00 DA

01 FC:1806

| \boxtimes | This statement qualifies under 37 C.F.R. §1.97, subsection (b) because (check all that apply) | | | | | | | | |
|-------------|--|---|---|---|--|--|--|--|--|
| | . 🔲 | (1) It is being filed within 3 months of the application filing date and is other the continued prosecution application under § 1.53(d) OR | | | | | | | |
| | | (2) | It is being filed within 3 months of entry of a national stage OR | | | | | | |
| | \boxtimes | (3) | • | date of the first Office Action on the merits | | | | | |
| | | (4) | | ng of a first Office Action after the filing of a on under § 1.114. | | | | | |
| | 37 C.F.R. $\S1.97(c)$. If this statement is being filed after the latest of: (1) three months beyon filing date of a national application; (2) three months beyond the date of entry of the nation stage as set forth in $\S1.491$ in an international application; or (3) the mailing date of a first action on the merits, but before the mailing date of the earlier of a final office action under or a notice of allowance under $\S1.311$, then: | | | | | | | | |
| | | a certification as specified in §1.97(e) is provided below; or | | | | | | | |
| | | a fee of \$180.00 as set forth in §1.17(p) is authorized below, enclosed, or included with the payment of other papers filed together with this statement. | | | | | | | |
| | office a | 7 C.F.R. §1.97(d). If this statement is being filed after the mailing date of the earlier of a final ffice action under §1.113 or a notice of allowance under §1.311, but before payment of the issue ee, then: | | | | | | | |
| | A. | a certification as specified in §1.97(e) is completed below; and | | | | | | | |
| | В. | a petition under 37 C.F.R. §1.97(d) requesting consideration of this statement is submitted herewith; and | | | | | | | |
| | C. | a fee of \$180.00 as set forth in §1.17(i)(1) is authorized below, enclosed, or included with the payment of other papers filed together with this statement. | | | | | | | |
| \boxtimes | Fee Authorization. The Commissioner is hereby authorized to charge the above-referenced fees of \$180.00 and charge any additional fees or credit any overpayment associated with this communication to Deposit Account No. <u>08-1641 (Docket No. 39740-0005A)</u> . | | | | | | | | |
| | , | | | Respectfully submitted, | | | | | |
| Dated: | August 4, 2004 | | | By: Ginger R. Dreger | | | | | |
| | | | | Reg. No. 33.055 | | | | | |

HELLER EHRMAN WHITE & MCAULIFFE LLP

Customer No. 25213 275 Middlefield Road

Menlo Park, CA 94025-3506

Telephone: (650) 324-7000/Facsimile: (650) 324-0638

DIPE (C)

TNEGRMATION DISCLOSURE STATEMENT

PTO-1449

ATTY. DOCKET NO.: SERIAL NO.: 39740-0005A 10/714,195

APPLICANT: Baker, et al.

| | | | FILING DATE: November | GROUP: 1634 | | | | | |
|--|---|-------------|----------------------------------|-------------|-------------|-------------------|----|--|--|
| | | U.S | . PATENT DOCUMENTS | | | | | | |
| EXAMINER'S INITIALS | PATENT NO. | DATE | NAME | CLASS | SUBCLASS | CLASS FILING DATE | | | |
| | 5,474,796 | 12/12/1995 | Thomas M. Brennan | 427 | 2.13 | | | | |
| · | | | | | | | | | |
| | | FORI | EIGN PATENT DOCUMENTS | | | | | | |
| EXAMINER'S | PATENT NO. | DATE | COUNTRY | CLASS | SUBCLASS | TRANSLATION | | | |
| INITIALS | | | | | | YES | NO | | |
| | | | | | | | | | |
| | | | | | | | | | |
| | | | | | | | | | |
| | OTHER DO | CUMENTS (| Including Author, Title, Date, P | ertinent Pa | iges, Etc.) | | | | |
| | Bhattacharjae, Arindam, et al., Proc. Natl. Acad. Sci. USA, Vol. 98, No. 24, 2001, pages 13790-13795 | | | | | | | | |
| | Golub, T.R., et al., Science, Vol. 286, 1999, pages 531-537 Martin, Katherine J., et al., Cancer Research. 60, 2000, pages 2232-2238 | | | | | | | | |
| | | | | | | | | | |
| | Ramaswamy, Sridhar, et. al., Proc. Natl. Acad. Sci. USA, 2001, Vol. 98, pages 15149-15154 Rimm, D.L., et al., Molecular Cloning Reveals Alternative Splice Forms of Human a(E) Catenin, Biochemical and Biophysical Research Communications, 1994, Vol. 203, pages 1691-1699 | | | | | | | | |
| ··· | Sorlie, Therese, et al., Proc. Natl. Acad. Sci. USA, 2001, Vol. 98, no. 19, pages 10869-10874 | | | | | | | | |
| West, Mike, et al., Proc. Natl. Acad. Sci. USA, 2001, Vol. 98, no. 20, pages 11462-11467 | | | | | | | | | |
| | <u> </u> | | | | | | | | |
| | 16-S322 | | | | | | | | |
| | Zhao, Renbin, et al., Analysis of p53-Regulated Gene Expression Patterns Using Oligonucleotide Arrays, Gene. & Development, 2000, Vol. 14, pages 981-993 | | | | | | | | |
| | | | | | | | | | |
| EXAMINER | | | DATE CONSIDERED | | | | | | |

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.